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Abstract
In pancreatic β-cells, mitochondria play a central role in coupling glucosemetabolism to insulin secretion. Chronic exposure of
β-cells to metabolic stresses impairs their function and potentially induces apoptosis. Little is known on mitochondrial
adaptation to metabolic stresses, i.e. high glucose, fatty acids or oxidative stress; being all highlighted in the pathogenesis of
type 2 diabetes. Here, human isletswere exposed for 3 days to 25 m glucose, 0.4 mpalmitate, 0.4 m oleate and transiently to
H2O2. Culture at physiological 5.6 m glucose served as no-stress control. Expression of mitochondrion-associated genes was
quantiﬁed, including the transcriptome ofmitochondrial innermembrane carriers. Targets of interestwere further evaluated at
the protein level. Three days after acute oxidative stress, no signiﬁcant alteration in β-cell function or apoptosis was detected in
human islets. Palmitate speciﬁcally increased expression of the pyruvate carriers MPC1 and MPC2, whereas the glutamate
carrier GC1 and the aspartate/glutamate carrier AGC1 were down-regulated by palmitate and oleate, respectively. High glucose
decreasedmRNA levels of key transcription factors (HNF4A, IPF1, PPARA and TFAM) and energy-sensor SIRT1. High glucose also
reduced expression of 11 mtDNA-encoded respiratory chain subunits. Interestingly, transcript levels of the carriers for
aspartate/glutamate AGC2, malate DIC and malate/oxaloacetate/aspartate UCP2 were increased by high glucose, a proﬁle
suggesting important mitochondrial anaplerotic/cataplerotic activities and NADPH-generating shuttles. Chronic exposure to
high glucose impaired glucose-stimulated insulin secretion, decreased insulin content, promoted caspase-3 cleavage and cell
death, revealing glucotoxicity. Overall, expression proﬁle of mitochondrion-associated genes was selectively modiﬁed by
glucose, delineating a glucotoxic-speciﬁc signature.
Introduction
In pancreatic β-cells, mitochondria participate to glucose-stimu-
lated insulin secretion (GSIS) by generating metabolic signals,
thereby connecting glucose usage to corresponding regulated in-
sulin exocytosis (1–4). Mitochondrial dysfunction impairs GSIS
and may promote dedifferentiation and ultimately death of the
β-cells, two events central in the pathogenesis of type 2 diabetes
(T2D) (5,6). Such defects are favored by chronic exposure to ele-
vated concentrations of glucose and fatty acids (7–11). The re-
spective contributions of speciﬁc diabetes-associated stresses
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to human β-cell dysfunction remain to be delineated through the
associated changes in speciﬁc gene expression. In contrast to the
acute potentiation of GSIS by fatty acids, chronic exposure in-
duces β-cell lipo-dysfunction characterized by elevated basal in-
sulin release and impaired glucose response, both in vitro (12) and
in vivo (13). Indeed, deleterious effects of fatty acid infusion have
been reported in individuals genetically predisposed for T2D (13).
Inmost in vitro studies, unsaturated fatty acids (e.g. oleate) do not
affect cell viability, whereas saturated fatty acids (e.g. palmitate)
may promote ER stress and apoptosis (11,12,14–16). The cytotox-
icity of palmitate increases with the exposure time and concomi-
tant high glucose concentrations, whereas it decreases with the
elevation of serum in the culture medium. The global glucolipo-
toxicity concept proposes that high glucose plus fatty acids
induce pleiotropic alterations accompanying obesity, the meta-
bolic syndrome and ultimately T2D (17,18). While the role of glu-
colipotoxicity in human physiopathology is still debated, its
molecular basis requires active nutrient metabolism, in turn
altering lipid partitioning and mitochondrial function with po-
tential production of reactive oxygen species (ROS) (19). Mito-
chondria are both a source of ROS and a sensitive target of
oxidative attacks (20–22). Accordingly, mitochondrial defects
and oxidative stress have been proposed to contribute to the dia-
betic state (19,23).
Candidate genes have been associated with both monogenic
diabetes (neonatal diabetes and Maturity-Onset Diabetes of the
Young, MODY) and polygenic forms of T2D (24,25). Among
them, mutations in the transcription factors HNF4A and IPF1/
PDX1 are associated with MODY1 and MODY4, respectively.
Their function is required for correct β-cell development, differ-
entiation and function (26). Recently, a point mutation in the
NADH-dependent histone deacetylase sirtuin SIRT1 gene was
identiﬁed in a family with T1D, revealing a monogenic form of
this autoimmune disease (27). Mitochondrial DNA (mtDNA) car-
ries only 37 genes that encode 13 polypeptides, 22 tRNAs and 2
ribosomal RNAs (3,5). The polypeptides encoded by the mtDNA
are all subunits of the OXPHOS complexes composing the elec-
tron transport chain, with complementary contribution of the
nuclear genome. Ablation in the β-cell of the nuclear gene encod-
ing the mitochondrial transcription factor A (Tfam) results in
mtDNA depletion and deﬁcient oxidative phosphorylation (28).
These mice are hyperglycemic, their islets exhibit impaired
GSIS and increased β-cell death; reproducing some characteris-
tics of human diabetes. Moreover, Pdx1 suppression in adult
mice reduces Tfam expression, coinciding with mitochondrial
dysfunction and defective GSIS (29). These mouse models with
selected gene alterations call for better delineation of the expres-
sion proﬁle of the mitochondrial machinery in human islets
under both normal and diabetogenic conditions.
Beside components of the TCA cycle and the electron trans-
port chain, the mitochondrial carriers are of particular interest,
although still poorly characterized, in particular regarding stress-
responses. These solute carriers transport a selection of metabo-
lites across the inner mitochondrial membrane and are encoded
by the nuclear SLC25 gene family (30,31). To date, ∼14 inherited
diseases (mostly neurological disorders) have been associated
with alterations in SLC25 genes, including the carriers for citrate/
isocitrate CIC (SLC25A1), aspartate/glutamate AGC1 (SLC25A12)
and AGC2 (SLC25A13), carnitine/acylcarnitine CAC (SLC25A20)
and glutamate GC1 (SLC25A22) (31). UCP2 (SLC25A8), originally
referred to as an uncoupling protein, has recently been character-
ized as amitochondrial C4metabolite transporter (32). Regarding
β-cells, the role of only some mitochondrial carriers has been
substantiated over the last years (33). For instance, we reported
that down-regulation of AGC1 or GC1 reduces GSIS (34,35).
Using pharmacological and siRNA approaches, similar conclu-
sions were raised for CIC, phosphate PiC (Slc25a3), malate (dicar-
boxylate) DIC (Slc25a10), 2-oxoglutarate OGC (Slc25a11), as
well as for the newly identiﬁed mitochondrial pyruvate carriers
MPC1 and MPC2 (33,36–41). Conversely, overexpression of the
NADH shuttle component AGC1 enhancesmitochondrial metab-
olism and GSIS (42). Recently, we characterized mitochondrion-
associated genes in INS-1E β-cells exposed to glucose or fatty
acids, revealing stress-speciﬁc signatures (43). Based on this pre-
vious work using a rat cell line, we are now reporting identiﬁca-
tion of mitochondrial molecular targets and their respective
gene expression in human islets in response to speciﬁcmetabolic
stresses, in order to deconstruct global glucolipotoxicity effects
and uncover the speciﬁc contributions of different stressors.
These diabetogenic conditions applied side by side in the same
study include exposure to high glucose concentrations, to satu-
rated versus unsaturated fatty acids, and to transient oxidative
stress.
Results
Effects of diabetogenic milieus on expression of
differentiation factors and energy sensors
Chronic effects ofmetabolic stresses on β-cell differentiation and
function were determined in human islets at the end of a 3-day
exposure to diabetogenic milieus, the physiological 5.6 m glu-
cose (G5.6) condition serving control. In an initial step to validate
the control islet transcriptome, this one was compared with
non-endocrine human HeLa and 143B cells. Messengers of the
β-cell-speciﬁc transcription factors HNF4A, IPF1 and MAFAwere
undetectable in non β-cells (Fig. 1A). In contrast, transcript levels
of TFAM and pyruvate carboxylase PC were higher in HeLa and
143B cells compared with islets. Interestingly, in control condi-
tions, we observed a negative correlation between the BMI of
donors (ranging from 23.2 to 28.6 kg/m2) and both IPF1 and
MAFA transcript levels (P < 0.05, Supplementary Material,
Fig. S1A–D). Expression of essential β-cell genes were repressed
by high glucose (G25), such as HNF4A and IPF1 involved in β-cell
differentiation (44), TFAM for mitochondrial biogenesis, the en-
ergy-sensor SIRT1 and the nuclear receptor PPARA regulating fat
metabolism (Fig. 1A). Analysis at the protein level in the same
islet batches revealed that for some genes protein levels did not
correlate with corresponding mRNA, suggesting gene-speciﬁc
post-transcriptional regulation. IPF1, TFAM and PGC1α proteins
were not changed in G25 condition, while SIRT1 and SIRT4 were
increased (Fig. 1B–D; Supplementary Material, Fig. S1E–G). In
agreement with previous report (45,46), G25 induced a strong
increase in the lipogenic enzyme acetyl-CoA carboxylase ACC,
whereas the levels of PC and glutamate dehydrogenase GLUD1
were unchanged. Regarding fatty acid exposure, palmitate (and
not oleate) up-regulated SIRT1, both at transcript and protein
levels (Fig. 1C). Oleate treatment decreased expression of MAFA
and IPF1 (Fig. 1A), the latter being also down at protein level
(Fig. 1B, D; Supplementary Material, Fig. S1E–G). Hydrogen perox-
ide exposure caused a speciﬁc repression of MAFA, conﬁrming
the high sensitivity oh this transcription factor to oxidative stress
(47). Expressions of other transcription factors and sirtuins were
not altered by H2O2 treatment, indicating selective effects in-
duced by oxidative stress. Taken together, data show that high
glucose modiﬁed expression of major differentiation factors
and energy sensors, while fatty acids modestly affected the
same genes, thereby showing stress-speciﬁc responses.
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Adaptation of mitochondrial respiratory chain subunits
and associated proteins
Regarding islet speciﬁcity, we ﬁrst observed that transcript
levels of numerous respiratory chain subunits were lower in
human islets compared with non-endocrine cells (Figs 2A and
3A). High glucose (G25), but not fatty acids, altered islet expres-
sion of respiratory chain subunits II (SDHB) and III (UQCRC2);
while all metabolic stress conditions preserved expression of
subunits I (NDUFA1), IV (COX4) and V (ATP5C1); of carriers asso-
ciated with ATP production (PiC for phosphate import or NCLX
controlling mitochondrial calcium homeostasis) and of mito-
chondrial structure (STOML2, PHB1) (Fig. 2A and B).G25-reduced
expression of 11 mtDNA-encoded (MT) subunits of OXPHOS
complexes: 7 subunits of complex I NADH dehydrogenase
(MT-ND1/ND6), 2 subunits of complex IV cytochrome c oxidase
(MT-CO1, MT-CO2) and 2 subunits of complex VATP synthase
(MT-ATP6,MT-ATP8). Consistent withmoderate effects induced
by fatty acids on transcription factors, oleate (not palmitate)
decreased transcript levels of MT-ND5, MT-ND6 and MT-
CO3 (Fig. 3A). Interestingly, all the metabolic stresses down-
regulated the complex V subunit MT-ATP8. Immunoblotting
revealed preservation at the protein level of the respiratory
chain complex subunits (Fig. 3B; Supplementary Material,
Fig. S2A–C). Of note, expressions of the OXPHOS subunits and
associated proteins were not altered by H2O2 treatment. Our re-
sults show that chronic exposure to high glucose caused a
marked and selective down-regulation of transcript levels en-
coded by mitochondrial genome.
Adaptation of mitochondrial solute carriers responsible
for metabolite transport
The second group of the mitochondrial components we ana-
lyzed mediates metabolite transport across the inner mito-
chondrial membrane. For those known to be required for GSIS
in rodent β-cell lines (33–37,39–43), expression was assessed
both at mRNA (Fig. 4A) and protein levels (Fig. 4B; Supplemen-
tary Material, Fig. S2A–C). As for respiratory chain subunits,
transcript levels of some solute carrierswere lower in human is-
lets compared with non-endocrine cells. G25 increased tran-
script levels (Fig. 4A) of the carriers for aspartate/glutamate
(AGC2) and malate (DIC and UCP2), the latter being also
Figure 1.Transcriptomeof β-cell differentiation factors and energy sensors in human islets after stress exposure. Islets obtained from threedonorswereexposed for 3 days
to deﬁned culture conditions: 25 m glucose (G25), 0.4 mpalmitate (Palm), 0.4 m oleate (Olea) and transient oxidative stress at Day 0 (200 µH2O2 for 10 min). Culture at
physiological 5.6 m glucose (G5.6) served as no-stress control. (A) Transcript levels ofmajor transcription factors, of the energy-sensor sirtuin SIRT1, of themitochondrial
enzymes pyruvate carboxylase PC and glutamate dehydrogenase 1GLUD1were quantiﬁed as described inMaterials andMethods. The values represent absolute numbers
of transcript moleculesmeasured in two human non-endocrine cell lines of reference (HeLa and 143B cells) and in three human islet preparations (ﬁlled circle represents
donor 1, triangle donor 2 and square donor 3), both in physiological (G5.6) and metabolically stressful conditions. Transcript levels were normalized to those of NUP155,
HDAC1 and TUBULIN and expressed as counts per 100 ng total RNA.Means of three independent experiments each done in duplicate are represented (horizontal bars). ND
not detectable (below detection limit) # P < 0.05, ### P < 0.005, comparing non-endocrine cells versus islets (G5.6); § P < 0.05, §§§ P < 0.005 versus corresponding G5.6 control
islets. (B andC) Representative immunoblottings showing levels of (B) the transcription factors IPF1, TFAM, the co-activator PGC1α, (C) the energy-sensors SIRT1 and SIRT4
from donor 2 (total extracts) under different experimental conditions. Total cell extracts as well as mitochondria (Mito) and nuclei isolated from HeLa cells were used as
additional controls. (D) Quantitative analysis of relative band densities normalized to ACTIN and TUBULIN as shown in (B, C) is presented as means ± SEM of at least four
independent experiments. Results are expressed as protein levels normalized to G5.6 values. *P < 0.05 versus G5.6 control islets.
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up-regulated at protein level (10) (Figs 4B and 5D; Supplemen-
tary Material, Figs S2C and S3B). Palmitate increased expression
of pyruvate carriers (MPC1 and MPC2) and decreased the gluta-
mate carrier (GC1), whereas oleate only down-regulated AGC1,
showing speciﬁc responses according to the nature of fatty
acids. Oxidative stress decreased UCP2 and GC1 transcripts.
We also measured protein levels of carnitine/acylcarnitine
carrier CAC, the rate-limiting mitochondrial transporter for β-
oxidation, which was not modiﬁed by metabolic stresses
(Fig. 4B; Supplementary Material, Fig. S2B and C). Results show
that glucose up-regulated some key mitochondrial carriers, in
particular AGC2 and DIC.
Effects of diabetogenic milieus on islet viability
To investigate whether the observed changes in gene expression
were associated with cytotoxic effects, cell death was quantiﬁed
at the end of the 3-day stress challenge. Control G5.6 cells exhib-
ited low basal apoptotic rate (Supplementary Material, Fig. S4C),
in the expected range of 1–3% (48). High glucose-induced apop-
tosis (2.5-fold cleaved CASPASE 3 in G25 versus control G5.6,
Fig. 5A). Lipotoxicity with apoptosis is regularly associated with
saturated fatty acids, whereas unsaturated fatty acids promote
mainly dysfunctional GSIS (11,12). Fatty acid treatments reported
to trigger apoptosis have usually been performed at low fetal calf
serum (FCS) (1%) or even in absence of serum (16).When cultured
Figure 2. Transcriptome of mitochondrial respiratory chain subunits and associated proteins in human islets after stress exposure. Transcript levels of (A) nuclear-
encoded subunits of the ﬁve OXPHOS complexes: NDUFA1 (complex I), SDHB (complex II), UQCRC2 (complex III), COX4 (complex IV) and ATP5C1 (complex V); (B) the
mitochondrial sodium/calcium antiporter NCLX, the phosphate carrier PiC, the stomatin-like protein 2 STOML2, the prohibitin PHB1 were quantiﬁed as described in
Figure 1A. Means of three independent experiments done in duplicate are represented (horizontal bars). # P < 0.05, ## P < 0.01, ### P < 0.005 comparing non-endocrine
cells versus islets (G5.6); § P < 0.05 versus corresponding G5.6 control islets.
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with standard FCS concentrations (5–10%), longer incubationper-
iods are required to observe cytotoxic effects. We opted for 5%
FCS in order to uncover the intrinsic effects of saturated versus
unsaturated fatty acids, without changing the standard culture
conditions. In accordance with previous reports (11,12), oleate
did not increase cell death. In our hands, palmitate did not induce
noticeable cytotoxicity in the different islet batches, exhibiting
resistance to oxidative stress (Fig. 5A; Supplementary Material,
Fig. S4C).
Among the different metabolic stresses tested side by side,
high glucose induced the main changes. Therefore, we investi-
gated further sugar effects on islet function and survival by
varying glucose concentrations and exposure time periods. In
agreement with previous results obtained after 72 h at G25,
SIRT1 and DIC were already up-regulated at protein level after
24 h at G16.7 and G30 (Supplementary Material, Fig. S3A and B).
In parallel, G16.7 and G30 markedly increased cleaved CASPASE
3 after 24 and 48 h (Fig. 5B). Of note, when islets were exposed
to high glucose for 24 h, apoptosis, CASPASE 3 cleavage and the
autophagy markers LC3-I and LC3-II were not systematically in-
creased in the different islet batches (Fig. 5C; Supplementary Ma-
terial, Fig. S3C). Interestingly, over short time periods ranging
from 6 to 12 h, apoptosis was induced in islets cultured at G5.6
(Fig. 5B), indicating that varying glucose concentrations in the
culture medium right after isolation is critical for the mainten-
ance of islets prior to transplantation. In agreement with the ob-
served activation of CASPASE 3 cleavage, G30 for 48 h induced a
2.0-fold increase in cell death (Fig. 5C) and increased expression
of LC3-I and LC3-II (Fig. 5D). Overall, exposure of human islets
for >24 h to high glucose increased autophagy markers and pro-
moted cell death, exhibiting prototypic glucotoxicity. In contrast,
no signiﬁcant cytotoxic effects were observed with fatty acids
and oxidative stress.
Effects of glucotoxicity on islet function
To examine whether the observed cytotoxic effects of high glu-
cosewere associatedwith ROS production and β-cell dysfunction,
superoxide generation and insulin secretion were determined in
parallel in the same islet batches. Superoxide levels measured
directly at the end of the 48 h culture were lower in G30 islets
compared with control G5.6 islets (Fig. 6A). These islets further
acutely stimulated with 16.7 m glucose for 1 h did not exhibit
signiﬁcant differences in superoxide generation (Fig. 6B). In par-
allel, insulin contents and the secretory responses were assessed
at the end of different culture periods. Islets exposed to G30 over
days exhibited gradual loss of their insulin contents, with only
20% left after 1 week compared with contemporary G5.6 controls
(Fig. 6C). Although islets cultured at control G5.6 also lost part of
their insulin contents, their secretory responses were progres-
sively enhanced with time in culture (Fig. 6D and E; Supplemen-
tary Material, Fig. S4A). In contrast, islets at G30 were not
responding to glucose stimulation already after 48 h and without
any recovery over the 1-week period. Consistentwith the absence
of persistent cytotoxic effects of H2O2, no signiﬁcant alteration in
insulin contents, GSIS and mitochondrial network was observed
in islets 3 days after acute oxidative stress (Supplementary Ma-
terial, Fig. S4A and B). Overall, chronic exposure to high glucose
markedly decreased insulin content and impaired GSIS in
human islets, leading to severe β-cell dysfunction.
Chronic effects of glucotoxicity on islet protein levels
Correspondence of gene expression atmRNAversus protein level
was rare after 3 days, possibly explained by rather long half-life of
human proteins.We then extended the analysis in islets exposed
to high glucose for 7 days. CASPASE 3 cleavage was enhanced by
high glucose, starting already at 24 h and over the 7 days of cul-
ture (Fig. 6F). IPF1 and TFAM protein levels were up-regulated
by chronic high glucose. This was also the case for adenosine
mono-phosphate kinase (AMPK), whereas its active phosphory-
lated form (pAMPK) was decreased. These data indicate that
islet cells escaping glucose-induced programmed cell death
maintained β-cell differentiation, insulin expression, mitochon-
drial biogenesis and AMP sensing.
Discussion
Inmost T2D, hyperglycemia appears as a result of signiﬁcant loss
of functional β-cells secondary to the exposure to a pathophysio-
logical environment, commonly referred to as glucolipotoxicity
(6,9,10,18,24,49). However, the respective contribution of the dif-
ferent components of the diabetogenic milieus to β-cell dysfunc-
tion, dedifferentiation and ultimately death remains unclear;
driven by speciﬁc changes in gene expression. Here, we explored
the speciﬁcity of molecular targets in response to the different
metabolic stresses investigated side by side in standardized con-
ditions. Figure 7A summarizes the changes in gene expression in
human islets following chronic exposure to high glucose, palmi-
tate or oleate, and oxidative stress; demonstrating stress-speciﬁc
signatures. Of note, the reported stress-responses were observed
on intact islets, being byessence composed of different cell types.
Somemarkers are speciﬁc for β-cells, such as IPF1 or insulin. Cor-
respondence with pure fraction of insulin-secreting INS-1E cells
is displayed on Figure 8, conﬁrming good correlation between
this rat cell line and human islets when exposed to diabetogenic
milieu (48). However, the respective contribution of each islet cell
type to the stress–response remains to be delineated.
Markers of oxidative stress
Transient exposure of INS-1E cells and rat islets to oxidative
stress alters mitochondrial gene expression and metabolism
and impairs β-cell function and survival (20,21,43). In human is-
lets, at day 3 post-stress, we observed preservation of GSIS and no
changes in cell death. Interestingly, transcript levels of the tran-
scription factor MAFA (47) and the C5 and C4 mitochondrial car-
riers GC1 and UCP2, respectively, were down-regulated as
reported in INS-1E cells (43), conferring to these targets a
stress-speciﬁc signature (Fig. 7A).
Figure 3. Expression of mtDNA-encoded respiratory chain subunits in human islets after stress exposure. (A) Transcript levels of mtDNA-encoded (MT) subunits of
OXPHOS complexes: NADH dehydrogenase ND1-–ND6 (complex I), ubiquinol:cytochrome c oxidoreductase CYB (complex III), cytochrome c oxidase CO1–CO3 (complex
IV), ATP synthase ATP6 and ATP8 (complex V), as well as the nuclear-encoded protein LETM1 and the mitochondrial ribosome small subunit protein S29 DAP3 were
quantiﬁed as described in Figure 1A. Means of three independent experiments done in duplicate are represented (horizontal bars). # P < 0.05, ## P < 0.01, ### P < 0.005
comparing non-endocrine cells versus islets (G5.6); § P < 0.05, §§§ P < 0.005 versus corresponding G5.6 control islets. (B) Representative immunoblotting showing protein
subunits of the 5 OXPHOS complexes from donor 2 (total extracts) under different experimental conditions. Total cell extracts and mitochondria (Mito) isolated from
HeLa cells were used as additional controls.
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Figure 4. Expression of mitochondrial metabolite carriers in human islets after stress exposure. (A) Transcript levels of the carriers for pyruvateMPC1 andMPC2, citrate/
isocitrate CIC, malate DIC, malate/oxaloacetate/aspartate UCP2, 2-oxoglutarate/malate OGC, aspartate/glutamate AGC1 and AGC2, glutamate GC1 were quantiﬁed as
detailed in Figure 1A. Means of three independent experiments done in duplicate are represented (horizontal bars). # P < 0.05, ### P < 0.005 comparing non-endocrine
cells versus islets (G5.6); § P < 0.05, §§ P < 0.01 versus corresponding G5.6 control islets. (B) Representative immunoblotting showing protein levels of the metabolite
carriers CIC, DIC, carnitine/acylcarnitine CAC (total extracts) in islets and HeLa subcellular fractions used as control.
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Mitochondrial markers of saturated and unsaturated
fatty acids
Previous studies reported that human islets exposed to palmitate
and oleate increase their basal insulin release and fail to respond
to stimulatory glucose (11,14,16). The absence of serum in the
culture medium worsens the effects of palmitate, inducing cell
death (16). Here, in the presence 5% FCS, neither palmitate nor
oleate did promote cytotoxic effects at physiological glucose con-
centration. Thus, the lipo-dysfunction developed by isolated
human islets was similar to the ones reported for primary rat is-
lets and INS-1E cells (43,50), as well as for islets from patients
with T2D (13). Discriminating fatty acids in the treatments uncov-
ered speciﬁc targets associated to the nature of the lipid (Fig. 7A).
Oleate decreased expression ofMAFA, IPF1 and the aspartate/glu-
tamate carrier AGC1, whereas palmitate up-regulated SIRT1 and
the pyruvate carriers MPC1/MPC2 while down-regulating GC1.
Palmitate was reported to repress expression of genes involved
in ATP production, including citrate synthase and mitochondrial
ATP synthase (16). Here, we observed that both fatty acids down-
regulated MT-ATP8, possibly contributing to the loss of GSIS.
Overall, present data showmodest impairment of mitochondrial
machinery and islet integrity by palmitate and oleate. According
to Robertson et al. (9), the relentless decline in TD2-associated β-
cell function and mass ascribed to lipotoxicity occurs only in a
context of preexisting hyperglycemia, whereas glucotoxicity
can occur in the absence of hyperlipidemia. Deﬁning the extent
to which hyperglycemia per se underlies these alterations is cru-
cial for the prevention of TD2. Recent studies inmice have shown
that many changes in islet differentiation and function asso-
ciatedwith diabetes are due to hyperglycemia only and can be re-
versed by blood glucose normalization (51,52).
Delineation of nuclear and mitochondrial markers
of glucotoxicity
Hyperglycemia is associated with β-cell dedifferentiation, altered
GSIS and increased cell death (5,7,9,10). A progressive deterior-
ation in β-cell function is a common ﬁnding in patients with
T2D. Similarly, in vitro exposure to high glucosemarkedly impairs
INS-1E cell function and survival (43). Here, chronic exposure of
human islets to G30 decreased insulin content, impaired GSIS
and induced apoptosis. Incidentally, our data validate the use
of 5.6 m as the optimal glucose concentration for human islets
in culture regarding insulin content and GSIS (Fig. 6B–D) and via-
bility (Fig. 6E).
Figure 7B shows the expression of key components of nuclear
differentiation factors and mitochondrial machineries being ex-
pressed in human islets and the ones being changed by chronic
Figure 5. Apoptosis in human islets after stress challenge. (A) Islets were exposed for 3 days to different culture conditions as detailed in Figure 1. Representative
immunoblotting showing the cleaved fragment of CASPASE 3 and TUBULIN from treated islets and HeLa cells used as non-endocrine controls. Quantitative analysis of
band densities normalized to TUBULIN from immunoblots is presented as means ± SEM of three independent experiments. Results are expressed as protein levels
normalized to the control value of G5.6. **P < 0.01 versus G5.6 control islets. (B–D) Human islets were exposed for different time periods to the indicated glucose
(G) concentrations. (B) Immunoblotting over time course of stress exposure showing cleaved CASPASE 3, the nuclear pore glycoprotein P62 and ACTIN. Thapsigargin
(Tg, 1 µ) served as positive control. (C) Cell apoptosis was measured by the Cell Death Detection ELISAPLUS assay. Values are means ± SEM of four independent
experiments, each done in triplicate. *P < 0.05 versus corresponding G5.6 controls. (D) Islets were exposed for 48 h to the indicated glucose concentrations or 1 μ
thapsigargin. Immunoblotting showing levels of the cleaved CASPASE 3, P62, the autophagosome markers LC3-I and LC3-II, SIRT4 and UCP2 from treated islets.
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high glucose. In line with rodent data (43,44), we observed down-
regulation of the transcription factors PPARA, TFAM, HNF4A and
IPF1 in human islets. The two latter are master regulators of
genes implicated in β-cell development and function (24–26),
such as the glucose transporter GLUT2, the glucose sensor gluco-
kinase GCK and insulin. TFAM, which is involved in themainten-
ance and transcription of mtDNA, is a direct target of IPF1/Pdx1
that binds to its promoter (29). In rat islets, defective Pdx1
Figure 6. Effects of glucotoxicity on islet function and protein levels. Isletswere exposed for the indicated time periods to the various glucose (G) concentrations. Culture at
G5.6 served as no-stress control. Then, the responses of chronically treated islets were acutely challenged for 60 min with 2.8 m (Basal) and 16.7 m (Stimul.) glucose
concentrations. (A and B) Superoxide generation measured in islets directly after the chronic 48 h G30 culture (A) or following further acute glucose stimulation (B; basal,
white bars; Stimul., black bars). (C) Time course of insulin contents in islets cultured at G5.6 (open circle) or exposed to G30 (ﬁlled circle). (D) At the end of the indicated
culture periods, insulin releasewasmeasured under Basal (white bars) and Stimul. (black bars) conditions. (E) Time course of secretory responses of islets cultured at G5.6
(open circle) or G30 (ﬁlled circle). Values aremeans ± SEM of at least four independent experiments, each done in triplicate. ***P < 0.005 versus corresponding G5.6 controls;
# P < 0.05, ### P < 0.005 versus corresponding basal secretion. (F) Representative immunoblotting showing levels of the indicated proteins from treated islets.
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down-regulates Tfam and mt-Nd1 and up-regulates Dic, along
with impaired mitochondrial activity (53). A striking observation
of the present study on human islets was the global down-regu-
lation ofmtDNA-encoded respiratory chain subunits by high glu-
cose (Fig. 7B). Transcription of mitochondrial genes is also
controlled by TFB1M and TFB2M, loss of the former being asso-
ciated with T2D (54). In mice, Tfb1m deﬁciency in β-cells causes
mitochondrial dysfunction and subsequently diabetes owing to
combined loss of β-cell function and mass (55).
High glucose also altered the expression of SIRT1 in human is-
lets. As sirtuin activity depends on NAD+/NADH ratio, it serves as
redox energy-sensor acting as a transcriptional activator via dea-
cetylase activity. In β-cells, the main SIRT1 targets are HNF-1α
and IPF1/Pdx1 (56). Taken together, our data suggest inter-
dependence between transcription regulators both in INS-1E
β-cells and human islets, represented in Figure 8, for which
chronic high glucose decreases SIRT1 and IPF1 expression, in
turn down-regulating TFAM and mtDNA-encoded respiratory
Figure 7. Stress-speciﬁc transcriptome of human islets after chronic exposure to diabetogenic milieus. (A) Changes in gene expression in human islets induced by the
different metabolic stresses, delineating stress-speciﬁc signatures. The mRNA levels of the genes labeled in green and red colors were found to be signiﬁcantly
(P < 0.05 versus G5.6) down- and up-regulated, respectively. (B) Global view of the expression of the genes at transcript level (node core) in islets exposed to 25 m
glucose (G25). The expressed genes were grouped using the Cytoscape software according to their protein subcellular localization (from the human database
neXtProt); cytoplasm, nucleus, mitochondrial inner membrane, matrix. Node shape: octagons show nuclear-encoded subunits of the ﬁve OXPHOS complexes,
rectangles represent mtDNA-encoded (MT) respiratory chain subunits, hexagons are mitochondrial carriers, circles are enzymes or other proteins, rounded rectangles
are transcription factors, and rhombi are energy-sensors. Colors reﬂect changes in expression levels in G25 versus G5.6 controls: green and red for signiﬁcant (P < 0.05)
down- and up-regulation, respectively; white no change.
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chain subunits. This alters mitochondrial ATP production and
consequently insulin secretion. In the long term, altered respira-
tory activity secondary to repressed mitochondrial gene expres-
sion may lead to increased susceptibility of β-cells to apoptosis.
Insulin secretion is triggered and maintained via integration
and production of signals by themitochondria (3,4). In particular,
pyruvate couples glycolysis to mitochondria, fueling the TCA
cycle and resulting in the generation of metabolic signals such
as ATP, ROS, citrate and glutamate (30,31). High glucose modiﬁed
neither MPC1 nor MPC2 expression, suggesting that pyruvate
transport was preserved in human islets. The associated de-
crease of respiratory chain subunits upon high glucose might
favor saturation of the electron transport chain, promoting cit-
rate export and consequently de novo lipid synthesis, an effect
substantiated by the observed increase of ACC protein (Figs 6E
and 8). Another unprecedented observation was the glucose-de-
pendent up-regulation ofmitochondrial carriers UCP2, AGC2 and
DIC at the transcript level in human islets (Fig. 7). UCP2 has been
implicated in numerous physiopathological conditions including
hyperglycemia and diabetes (5,10). It was proposed that these
effects of UCP2 were mediated by mitochondrial uncoupling ac-
tivity, regulating ROS production. However, the recent demon-
stration of C4 metabolite transport properties of UCP2 shed a
new light on the observed up-regulation of UCP2 secondary to
hyperglycemia (32). Increasing mitochondrial export capacity of
oxaloacetate and malate would reduce TCA cycle activity, there-
by lowering the redox pressure and ATP production. The mito-
chondrial redox pressure is also contributed by NADH shuttles,
having redundant routes in β-cells (33), AGC2 being involved in
the malate-aspartate shuttle (34,42) as well as glutamate metab-
olism (57). By up-regulating AGC2 upon high glucose exposure
(Fig. 7B), human islets could increase the capacity of aerobic gly-
colysis. Finally, themalate carrier DIC is a critical shuttle compo-
nent for cytosolic NADPH production mediated by pyruvate
cycling (37,58). In neurons, DIC mediates glutathione transport
and the mitochondrial GSH pool, which participates to ROS
homeostasis (59). In β-cells, the NADPH oxidase NOX2 negatively
modulatesGSIS by promoting ROS generation and reducing cAMP
(22). According to these data, up-regulation of both DIC and UCP2
in human islets exposed to high glucose (Fig. 7B) could decrease
ROS production within mitochondria, while generating cytosolic
ROS, in turn inhibiting insulin release. Collectively, the activity of
each of these mitochondrial carriers lowers the contribution of
glucose tomitochondrial oxidativemetabolism, suggesting ami-
tohormetic response implicating UCP2, AGC2 and DIC. Drugs act-
ing on mitochondrial carrier activity such as metformin and
thiazolidinediones, which regulate UCP2 and MPC, respectively,
could be beneﬁcial to restore metabolic function (60,61).
Conclusion
Hyperglycemic conditions induced down-regulation of 18 genes
and up-regulation of 3 genes, uncovering a stress-speciﬁc signa-
ture in human islets. Bioinformatics analysis of the expression
proﬁles delineated comprehensive network and established pu-
tative molecular targets as well as related network in human
Figure 8. Putative molecular targets and related network in human islets and INS-1E β-cells secondary to glucotoxic insult. Network of genes with altered expression
upon G25 treatment, either up- (red) or down-regulated (green). Gray nodes represent molecular targets that were obtained from network expansion using
GeneMANIA (http://www.genemania.org/), providing network links between the initial 21 altered human genes. Border colors shows the identiﬁed transcriptional
alterations in INS-1E cells (43): black no change; gray not tested. The connections are represented as follows: blue lines show proteins acting in the same pathway; red
lines physical interactions; gray lines genes that are co-expressed or sharing same domains.
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islets secondary to glucotoxic insult. Thus, high glucose impedes
primarily islet function through mitochondrial metabolism,
leading to impaired GSIS and islet mass.
Materials and Methods
Cell culture and treatments
HeLa and 143B cells, used as control human non-endocrine cells,
were grown in Dulbecco’smodiﬁed Eaglemedium supplemented
with 10% heat-inactivated fetal bovine serum, 100 U/ml penicil-
lin, 100 µg/ml streptomycin and 2 m -glutamine in 5% CO2 at
37°C (62). Human islets were isolated from pancreases of de-
ceased multiorgan donors (n = 14), who had provided written in-
formed consent (ECIT consortium). None of the donors were
diagnosed with metabolic syndrome or diabetes (see description
in SupplementaryMaterial, Table S1). Donors had an average BMI
of 25.1 ± 3.6 kg/m2 and age of 53.1 ± 7.5 years. Islets were main-
tained for standard recovery period of time (1–4 days) in CRML-
1066medium at 5.6 m glucose supplementedwith 10% heat-in-
activated FCS and used for experiments straight away without
shipping maneuver (isolation and experiment being performed
in the same institution). Then, islets were hand-picked, washed
and further cultured for the indicated culture period in 6-well
plates (Falcon, OmniLab, Mettmenstetten, Switzerland) in the
presence of 5% FCS at either physiological 5.6 m glucose (G5.6,
control) or exposed to high glucose (25 m, G25 or 30 m, G30).
In parallel, islets were also exposed to 0.4 m palmitate (satu-
rated fatty acid C16:0; Palm) or with 0.4 m oleate (unsaturated
fatty acid C18:1; Olea) in the presence of 0.5% BSA in control me-
dium as detailed previously (14,43). Stock solutions of fatty acids
(palmitate and oleate; Sigma-Aldrich, St Louis, MO, USA) bound
to BSA were adjusted to 10 m fatty acids using 1.8 m fatty
acid-free BSA before storage at −20°C under nitrogen. Additional-
ly, islets were acutely treated at Day 0 of experiment with single
transient oxidative stress (200 µ H2O2 for 10 min) (21). Islets ex-
posure to each type of stresses was performed in parallel with
each batch of human islets.
Establishment of mitochondrial transcriptome
We designed a human molecular screen based on NanoString®
nCounter system (Seattle, WA, USA) allowing captures and
counts of individual cellular mRNA transcripts not requiring
cDNA synthesis and more sensitive than micro-arrays (62–64).
After a pilot experiment in order to validate our probes using
HeLa cells (data not shown; probes ∼100 bases long are described
in Supplementary Material, Table S2), human islets (200 islets/
well) were exposed to the different stresses as described above.
Three independent experiments with the same culture condi-
tions were performed (donors 1–3 described in Supplementary
Material, Table S1) and for every experiment each culture condi-
tion was done in duplicate. Total RNAwas extracted with TRIzol
reagent and all samples were quantiﬁed (QuBit from Invitrogen)
at high precision level using ﬂuorescent speciﬁc dyes. Quality
controls of RNA samples were performed before each analysis
(Agilent 2100 Bioanalyzer, Santa Clara, CA, USA). Then, 100 ng
of total RNA were mixed with nCounter ﬂuorescence-reporter
and biotin-capture probes in hybridization buffer before over-
night incubation at 65°C, allowing quantiﬁcation of 45 gene tran-
scripts in a single run. Following hybridization, samples were
immediately processed with the PrepStation and subsequently
analyzed on an nCounter Digital Analyzer (iGE3 genomics plat-
form, University of Geneva) (62). Reporter probes, representing
individual copies of mRNA, were scanned for quantiﬁcation
and tabulated as counts of individual mRNA transcripts (63,64).
For this experimental design, statistics have been performed on
the mean values obtained from the duplicate for each independ-
ent experiment (n = 3). Data were normalized to the following
housekeeping genes: nuclear pore complex protein NUP155, his-
tone deacetylase HDAC1 and TUBULIN to normalize the data;
showingno statistical differences betweenconditions. Transcript
levels of gene of interest were expressed as mRNA molecule
counts per 100 ng total RNA.
Immunoblotting
At the end of the culture period, protein extracts were harvested
from 200 islets/well in lysis buffer (56). Total cell extracts as well
as mitochondria and nuclei isolated from HeLa cells were
prepared as described (21) and used as human non-endocrine
controls. Proteins from total cell extracts (15 μg/lane) and mito-
chondria (10 μg/lane) were separated by 10–12% SDS–PAGE before
transfer onto polyvinylidene ﬂuoridemembrane. Themembrane
was blocked with polyvinyl alcohol and then probed overnight at
4°C with: goat polyclonal antibodies against IPF1 (1:50 000, pro-
vided by C. Wright, Vanderbilt University, USA), PGC1α, TFAM,
SREBP1c (1 : 1000, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), UCP2 (1 : 1000, Alpha Diagnostic, San Antonio, TX, USA)
and SIRT4 (1 : 1000, Abcam Inc., Cambridge, MA, USA); mouse
monoclonal antibodies against SIRT1 (1 : 1000), ACTIN (1 : 20 000,
Chemicon-Millipore, Zug, Switzerland), TUBULIN (1 : 100 000,
Sigma-Aldrich) and ﬁve subunits of OXPHOS complexes (1 : 15
000, MitoSciences, Eugene, OR, USA); rabbit polyclonal antibodies
against CIC, DIC, CAC (1 : 10 000, provided by F. Palmieri, Univer-
sity of Bari, Italy), P62 (1 : 1000, Proteintech, Chicago, IL, USA),
LC3 (1 : 1000, Abcam Inc., Cambridge, MA, USA), AMPK, p-AMPK,
ACC, FAS and cleaved CASPASE-3 (1 : 1000 dilution, Cell Signaling
Technology, Danvers, MA, USA). After washing,membraneswere
incubated for 1 h at RT with secondary horseradish peroxidase-
conjugated anti-goat (1 : 10 000, Amersham Biosciences, UK), anti-
mouse or anti-rabbit antibodies IgG (1 : 10 000, Sigma-Aldrich)
according to primary antibodies. Proteins were visualized by
chemiluminescence (ECL #RPN2135, Amersham), analyzed with
the ChemiDoc XRS System (Bio-Rad, Hercules, CA) and bands
were quantiﬁed with Scion Image software (Scion Corporation,
Frederick, MD, USA).
Apoptosis, insulin secretion and superoxide
measurements
After recovery, human islets were cultured (100 islets/well) in 6-
well plates and exposed for 24 and 48 h at G5.6 and G30. Apop-
tosis was quantiﬁed using the Cell Death Detection ELISAPLUS
kit (Roche Diagnostics, Basel, Switzerland) according to theman-
ufacturer’s instructions. Alternatively, cell death was estimated
by CASPASE 3 cleavage activation by immunoblotting (see above).
For superoxide measurements, islets were cultured at G5.6 and
G30 for 48 h. Then, islets were hand-picked, washed and chal-
lenged for insulin secretory response at basal 2.8 m and stimu-
latory 16.7 m glucose concentrations for 60 min as detailed
previously (56). Secreted and total cellular insulin contents
were quantiﬁed by radioimmunoassay (Linco Research Inc.,
St. Charles, MO, USA). Protein concentrations were determined
by Bradford assay (Pierce, Rockford, IL, USA). For superoxide gen-
eration, groups of 20 islets were loaded with dihydroethidine
(DHE 25 μ, Sigma-Aldrich) at either 5.6 or 30 m glucose. Fluor-
escence was monitored in a thermostated plate reader (Fluostar
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Optima, BMG Labtechnologies, Offenburg, Germany) for 60 min
with excitation at 544 nm and emission at 590 nm and slope
served to calculate superoxide generation as described (22).
Cytoscape
Gene expression data were analyzed by integrating knowledge-
base (neXtProt) data (65) with differential subcellular expression
information in order to establish gene associations. Comprehen-
sive map of putative links between identiﬁed genes and molecu-
lar targets obtained from GeneMANIA-based network expansion
was drawn with Cytoscape software version 2.8.2 (66).
Statistical analysis
All data were analyzed with the IBM SPSS Statistics 20.0 software
(SPSS Inc., Chicago, IL, USA). Statistical tests between each stress
condition and the control G5.6 values were performed using one-
wayANOVAanalysis followed byDunnet post hoc test. Differences
betweenhuman cell lines and control islets (G5.6) valueswere as-
sessed by a two-tailed paired t-test using Prism software. Results
are presented asmeans ± SEM. A P-value of <0.05 was considered
statistically signiﬁcant.
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We are grateful to Patrick Descombes and Didier Chollet (Univer-
sity of Geneva) for excellent technical assistance. Human islets
were provided through the Juvenile Diabetes Research Founda-
tion (JDRF) award 1-RSC-2014-100-I-X (ECIT Islet for Basic Re-
search program).
Conﬂict of Interest statement. None declared.
Funding
This work was supported by the State of Geneva and the Swiss
National Science Foundation (310030B_135704, 31003A_146984
to P.M.).
References
1. Maechler, P. and Wollheim, C.B. (2001) Mitochondrial func-
tion in normal and diabetic beta-cells. Nature, 414, 807–812.
2. Jitrapakdee, S., Wutthisathapornchai, A., Wallace, J.C. and
MacDonald, M.J. (2010) Regulation of insulin secretion: role
of mitochondrial signalling. Diabetologia, 53, 1019–1032.
3. Maechler, P., Li, N., Casimir, M., Vetterli, L., Frigerio, F. and
Brun, T. (2010) Role of mitochondria in beta-cell function
and dysfunction. Adv. Exp.Med.Biol., 654, 193–216.
4. Prentki, M., Matschinsky, F.M. and Madiraju, S.R. (2013) Meta-
bolic signaling in fuel-induced insulin secretion. Cell Metabol-
ism, 18, 162–185.
5. Supale, S., Li, N., Brun, T. and Maechler, P. (2012) Mitochon-
drial dysfunction in pancreatic beta cells. Trends Endocrinol
Metabolism, 23, 477–487.
6. Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A.
and Butler, P.C. (2003) Beta-cell deﬁcit and increased beta-
cell apoptosis in humans with type 2 diabetes. Diabetes, 52,
102–110.
7. Ling, Z. and Pipeleers, D.G. (1996) Prolonged exposure of
human beta cells to elevated glucose levels results in sus-
tained cellular activation leading to a loss of glucose regula-
tion. J Clin Invest, 98, 2805–2812.
8. Maedler, K., Spinas, G.A., Lehmann, R., Sergeev, P., Weber, M.,
Fontana, A., Kaiser, N. and Donath, M.Y. (2001) Glucose in-
duces beta-cell apoptosis via upregulation of the Fas receptor
in human islets. Diabetes, 50, 1683–1690.
9. Robertson, R.P., Harmon, J., Tran, P.O. and Poitout, V. (2004)
Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative
stress in type 2 diabetes. Diabetes, 53(Suppl. 1), S119–S124.
10. Bensellam, M., Laybutt, D.R. and Jonas, J.C. (2012) The mo-
lecular mechanisms of pancreatic beta-cell glucotoxicity: re-
cent ﬁndings and future research directions. Mol. Cell.
Endocrinol., 364, 1–27.
11. Maedler, K., Oberholzer, J., Bucher, P., Spinas, G.A. and Do-
nath, M.Y. (2003) Monounsaturated fatty acids prevent the
deleterious effects of palmitate and high glucose on human
pancreatic beta-cell turnover and function. Diabetes, 52,
726–733.
12. El-Assaad, W., Buteau, J., Peyot, M.L., Nolan, C., Roduit, R.,
Hardy, S., Joly, E., Dbaibo, G., Rosenberg, L. and Prentki, M.
(2003) Saturated fatty acids synergize with elevated glucose
to cause pancreatic beta-cell death. Endocrinology, 144,
4154–4163.
13. Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Ber-
ria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo,
R. and Cusi, K. (2003) A sustained increase in plasma free fatty
acids impairs insulin secretion in nondiabetic subjects genet-
ically predisposed to develop type 2 diabetes. Diabetes, 52,
2461–2474.
14. Frigerio, F., Brun, T., Bartley, C., Usardi, A., Bosco, D., Ravnsk-
jaer, K., Mandrup, S. and Maechler, P. (2010) Peroxisome
proliferator-activated receptor alpha (PPARalpha) protects
against oleate-induced INS-1E beta cell dysfunction by pre-
serving carbohydrate metabolism. Diabetologia, 53, 331–340.
15. Igoillo-Esteve, M., Marselli, L., Cunha, D.A., Ladriere, L., Ortis,
F., Grieco, F.A., Dotta, F., Weir, G.C., Marchetti, P., Eizirik, D.L.
et al. (2010) Palmitate induces a pro-inﬂammatory response in
human pancreatic islets thatmimics CCL2 expression by beta
cells in type 2 diabetes. Diabetologia, 53, 1395–1405.
16. Cnop, M., Abdulkarim, B., Bottu, G., Cunha, D.A., Igoillo-Es-
teve, M., Masini, M., Turatsinze, J.V., Griebel, T., Villate, O.,
Santin, I. et al. (2014) RNA sequencing identiﬁes dysregulation
of the human pancreatic islet transcriptome by the saturated
fatty acid palmitate. Diabetes, 63, 1978–1993.
17. Cnop,M. (2008) Fatty acids and glucolipotoxicity in the patho-
genesis of Type 2 diabetes. Biochem. Soc.Trans., 36, 348–352.
18. Poitout, V., Amyot, J., Semache, M., Zarrouki, B., Hagman, D.
and Fontes, G. (2010) Glucolipotoxicity of the pancreatic
beta cell. Biochim. Biophys. Acta, 1801, 289–298.
19. Li, N., Frigerio, F. and Maechler, P. (2008) The sensitivity of
pancreatic beta-cells to mitochondrial injuries triggered
by lipotoxicity and oxidative stress. Biochem. Soc.Trans., 36,
930–934.
20. Maechler, P., Jornot, L. and Wollheim, C.B. (1999) Hydrogen
peroxide alters mitochondrial activation and insulin secre-
tion in pancreatic beta cells. J. Biol. Chem., 274, 27905–27913.
21. Li, N., Brun, T., Cnop, M., Cunha, D.A., Eizirik, D.L. andMaech-
ler, P. (2009) Transient oxidative stress damages mitochon-
drial machinery inducing persistent beta-cell dysfunction. J.
Biol. Chem., 284, 23602–23612.
22. Li, N., Li, B., Brun, T., Deffert-Delbouille, C., Mahiout, Z., Daali,
Y., Ma, X.J., Krause, K.H. and Maechler, P. (2012) NADPH
5282 | Human Molecular Genetics, 2015, Vol. 24, No. 18
oxidase NOX2 deﬁnes a new antagonistic role for reactive
oxygen species and cAMP/PKA in the regulation of insulin se-
cretion. Diabetes, 61, 2842–2850.
23. Lu, H., Koshkin, V., Allister, E.M., Gyulkhandanyan, A.V. and
Wheeler, M.B. (2010) Molecular and metabolic evidence for
mitochondrial defects associated with beta-cell dysfunction
in a mouse model of type 2 diabetes. Diabetes, 59, 448–459.
24. Ashcroft, F.M. and Rorsman, P. (2012) Diabetes mellitus and
the beta cell: the last ten years. Cell, 148, 1160–1171.
25. Thomsen, S.K. and Gloyn, A.L. (2014) The pancreatic beta cell:
recent insights from human genetics. Trends Endocrinol. Me-
tabolism, 25, 425–434.
26. Schwitzgebel, V.M., Mamin, A., Brun, T., Ritz-Laser, B., Zaiko,
M., Maret, A., Jornayvaz, F.R., Theintz, G.E., Michielin, O., Mel-
loul, D. et al. (2003) Agenesis of human pancreas due to de-
creased half-life of insulin promoter factor 1. J. Clin.
Endocrinol.Metabolism, 88, 4398–4406.
27. Biason-Lauber, A., Boni-Schnetzler, M., Hubbard, B.P., Bou-
zakri, K., Brunner, A., Cavelti-Weder, C., Keller, C., Meyer-
Boni, M., Meier, D.T., Brorsson, C. et al. (2013) Identiﬁcation
of a SIRT1 mutation in a family with type 1 diabetes. Cell Me-
tabolism, 17, 448–455.
28. Silva, J.P., Kohler, M., Graff, C., Oldfors, A., Magnuson, M.A.,
Berggren, P.O. and Larsson, N.G. (2000) Impaired insulin se-
cretion and beta-cell loss in tissue-speciﬁc knockout mice
with mitochondrial diabetes. Nat. Genet., 26, 336–340.
29. Gauthier, B.R., Wiederkehr, A., Baquie, M., Dai, C., Powers, A.
C., Kerr-Conte, J., Pattou, F., MacDonald, R.J., Ferrer, J. and
Wollheim, C.B. (2009) PDX1 deﬁciency causes mitochondrial
dysfunction and defective insulin secretion through TFAM
suppression. Cell Metabolism, 10, 110–118.
30. Palmieri, F. (2013) The mitochondrial transporter family
SLC25: identiﬁcation, properties and physiopathology. Mol.
Aspects Med., 34, 465–484.
31. Palmieri, F. (2014) Mitochondrial transporters of the SLC25
family and associated diseases: a review. J. Inherited Metabolic
Disease, 37, 565–575.
32. Vozza, A., Parisi, G., De Leonardis, F., Lasorsa, F.M., Castegna,
A., Amorese, D., Marmo, R., Calcagnile, V.M., Palmieri, L., Ric-
quier, D. et al. (2014) UCP2 transports C4 metabolites out of
mitochondria, regulating glucose and glutamine oxidation.
Proc. Natl Acad. Sci. USA, 111, 960–965.
33. Huypens, P.R., Huang, M. and Joseph, J.W. (2012) Overcoming
the spatial barriers of the stimulus secretion cascade in pan-
creatic beta-cells. Islets, 4, 1–16.
34. Casimir, M., Rubi, B., Frigerio, F., Chaffard, G. andMaechler, P.
(2009) Silencing of the mitochondrial NADH shuttle compo-
nent aspartate-glutamate carrier AGC1/Aralar1 in INS-1E
cells and rat islets. Biochem. J., 424, 459–466.
35. Casimir, M., Lasorsa, F.M., Rubi, B., Caille, D., Palmieri, F.,
Meda, P. and Maechler, P. (2009) Mitochondrial glutamate
carrier GC1 as a newly identiﬁed player in the control of glu-
cose-stimulated insulin secretion. J. Biol. Chem., 284, 25004–
25014.
36. Joseph, J.W., Jensen, M.V., Ilkayeva, O., Palmieri, F., Alarcon,
C., Rhodes, C.J. and Newgard, C.B. (2006) The mitochondrial
citrate/isocitrate carrier plays a regulatory role in glucose-sti-
mulated insulin secretion. J. Biol. Chem., 281, 35624–35632.
37. Huypens, P., Pillai, R., Sheinin, T., Schaefer, S., Huang, M.,
Odegaard, M.L., Ronnebaum, S.M., Wettig, S.D. and Joseph,
J.W. (2011) The dicarboxylate carrier plays a role inmitochon-
drial malate transport and in the regulation of glucose-sti-
mulated insulin secretion from rat pancreatic beta cells.
Diabetologia, 54, 135–145.
38. Odegaard, M.L., Joseph, J.W., Jensen, M.V., Lu, D., Ilkayeva, O.,
Ronnebaum, S.M., Becker, T.C. and Newgard, C.B. (2010) The
mitochondrial 2-oxoglutarate carrier is part of a metabolic
pathway that mediates glucose- and glutamine-stimulated
insulin secretion. J. Biol. Chem., 285, 16530–16537.
39. Herzig, S., Raemy, E., Montessuit, S., Veuthey, J.L., Zamboni,
N., Westermann, B., Kunji, E.R. andMartinou, J.C. (2012) Iden-
tiﬁcation and functional expression of the mitochondrial
pyruvate carrier. Science, 337, 93–96.
40. Patterson, J.N., Cousteils, K., Lou, J.W., Manning Fox, J.E.,
MacDonald, P.E. and Joseph, J.W. (2014) Mitochondrial
metabolism of pyruvate is essential for regulating glucose-
stimulated insulin secretion. J. Biol. Chem., 289, 13335–13346.
41. Vigueira, P.A., McCommis, K.S., Schweitzer, G.G., Remedi, M.
S., Chambers, K.T., Fu, X., McDonald, W.G., Cole, S.L., Colca,
J.R., Kletzien, R.F. et al. (2014) Mitochondrial pyruvate carrier
2 hypomorphism in mice leads to defects in glucose-stimu-
lated insulin secretion. Cell Reports, 7, 2042–2053.
42. Rubi, B., del Arco, A., Bartley, C., Satrustegui, J. and Maechler,
P. (2004) Themalate-aspartateNADHshuttlemember Aralar1
determines glucose metabolic fate, mitochondrial activity,
and insulin secretion in beta cells. J. Biol. Chem., 279, 55659–
55666.
43. Brun, T., Scarcia, P., Li, N., Gaudet, P., Duhamel, D., Palmieri, F.
andMaechler, P. (2013) Changes inmitochondrial carriers ex-
hibit stress-speciﬁc signatures in INS-1E beta-cells exposed
to glucose versus fatty acids. PLoS ONE, 8, e82364.
44. Goehring, I., Sauter, N.S., Catchpole, G., Assmann, A., Shu, L.,
Zien, K.S., Moehlig, M., Pfeiffer, A.F., Oberholzer, J., Willmit-
zer, L. et al. (2011) Identiﬁcation of an intracellular metabolic
signature impairing beta cell function in the rat beta cell line
INS-1E and human islets. Diabetologia, 54, 2584–2594.
45. Brun, T., Roche, E., Kim, K.H. and Prentki, M. (1993) Glucose
regulates acetyl-CoA carboxylase gene expression in a pan-
creatic beta-cell line (INS-1). J. Biol. Chem., 268, 18905–18911.
46. Brun, T., Assimacopoulos-Jeannet, F., Corkey, B.E. and
Prentki, M. (1997) Long-chain fatty acids inhibit acetyl-CoA
carboxylase gene expression in the pancreatic beta-cell line
INS-1. Diabetes, 46, 393–400.
47. Guo, S., Dai, C., Guo, M., Taylor, B., Harmon, J.S., Sander, M.,
Robertson, R.P., Powers, A.C. and Stein, R. (2013) Inactivation
of speciﬁc beta cell transcription factors in type 2 diabetes. J.
Clin. Invest., 123, 3305–3316.
48. Ardestani, A., Paroni, F., Azizi, Z., Kaur, S., Khobragade, V.,
Yuan, T., Frogne, T., Tao, W., Oberholzer, J., Pattou, F. et al.
(2014) MST1 is a key regulator of beta cell apoptosis and dys-
function in diabetes. Nat. Med., 20, 385–397.
49. Lee, M.S. (2014) Role of islet beta cell autophagy in the patho-
genesis of diabetes. Trends Endocrinol. Metabolism, 25, 620–627.
50. Zhou, Y.P. andGrill, V.E. (1994) Long-termexposure of rat pan-
creatic islets to fatty acids inhibits glucose-induced insulin
secretion and biosynthesis through a glucose fatty acid
cycle. J. Clin. Invest., 93, 870–876.
51. Brereton, M.F., Iberl, M., Shimomura, K., Zhang, Q., Adriaens-
sens, A.E., Proks, P., Spiliotis, I.I., Dace, W., Mattis, K.K., Ram-
racheya, R. et al. (2014) Reversible changes in pancreatic islet
structure and function produced by elevated blood glucose.
Nat. Commun., 5, 4639.
52. Wang, Z., York, N.W., Nichols, C.G. and Remedi, M.S. (2014)
Pancreatic beta cell dedifferentiation in diabetes and rediffer-
entiation following insulin therapy. Cell Metabolism, 19, 872–
882.
53. Gauthier, B.R., Brun, T., Sarret, E.J., Ishihara, H., Schaad, O.,
Descombes, P. and Wollheim, C.B. (2004) Oligonucleotide
Human Molecular Genetics, 2015, Vol. 24, No. 18 | 5283
microarray analysis reveals PDX1 as an essential regulator of
mitochondrial metabolism in rat islets. J. Biol. Chem., 279,
31121–31130.
54. Koeck, T., Olsson, A.H., Nitert,M.D., Sharoyko, V.V., Ladenvall,
C., Kotova, O., Reiling, E., Ronn, T., Parikh, H., Taneera, J. et al.
(2011) A common variant in TFB1M is associated with re-
duced insulin secretion and increased future risk of type 2
diabetes. Cell Metabolism, 13, 80–91.
55. Sharoyko, V.V., Abels, M., Sun, J., Nicholas, L.M., Mollet, I.G.,
Stamenkovic, J.A., Gohring, I., Malmgren, S., Storm, P., Fadis-
ta, J. et al. (2014) Loss of TFB1M results in mitochondrial dys-
function that leads to impaired insulin secretion and
diabetes. Hum. Mol. Genet., 23, 5733–5749.
56. Vetterli, L., Brun, T., Giovannoni, L., Bosco, D. andMaechler, P.
(2011) Resveratrol potentiates glucose-stimulated insulin
secretion in INS-1E beta-cells and human islets through a
SIRT1-dependent mechanism. J. Biol.Chem., 286, 6049–6060.
57. Vetterli, L., Carobbio, S., Pournourmohammadi, S., Martin-Del-
Rio, R., Skytt, D.M.,Waagepetersen, H.S., Tamarit-Rodriguez, J.
andMaechler, P. (2012)Delineationof glutamatepathways and
secretory responses in pancreatic islets with beta-cell-speciﬁc
abrogation of the glutamate dehydrogenase. Mol.Biol. Cell, 23,
3851–3862.
58. Jensen, M.V., Joseph, J.W., Ronnebaum, S.M., Burgess, S.C.,
Sherry, A.D. and Newgard, C.B. (2008) Metabolic cycling in
control of glucose-stimulated insulin secretion.Am. J. Physiol.
Endocrinol. Metabolism, 295, E1287–E1297.
59. Wilkins, H.M., Kirchhof, D., Manning, E., Joseph, J.W. and Lin-
seman, D.A. (2013) Mitochondrial glutathione transport is a
key determinant of neuronal susceptibility to oxidative and
nitrosative stress. J. Biol. Chem., 288, 5091–5101.
60. Divakaruni, A.S., Wiley, S.E., Rogers, G.W., Andreyev, A.Y.,
Petrosyan, S., Loviscach, M., Wall, E.A., Yadava, N., Heuck,
A.P., Ferrick, D.A. et al. (2013) Thiazolidinediones are acute,
speciﬁc inhibitors of the mitochondrial pyruvate carrier.
Proc. Natl Acad. Sci. USA, 110, 5422–5427.
61. Donadelli, M., Dando, I., Fiorini, C. and Palmieri, M. (2014)
UCP2, a mitochondrial protein regulated at multiple levels.
Cell. Mol Life Sci, 71, 1171–1190.
62. Jourdain, A.A., Koppen, M., Wydro, M., Rodley, C.D., Lightow-
lers, R.N., Chrzanowska-Lightowlers, Z.M. and Martinou, J.C.
(2013) GRSF1 regulates RNA processing inmitochondrial RNA
granules. Cell Metabolism, 17, 399–410.
63. Geiss, G.K., Bumgarner, R.E., Birditt, B., Dahl, T., Dowidar, N.,
Dunaway, D.L., Fell, H.P., Ferree, S., George, R.D., Grogan, T.
et al. (2008) Direct multiplexed measurement of gene expres-
sionwith color-coded probe pairs.Nat. Biotechnol., 26, 317–325.
64. Fortina, P. and Surrey, S. (2008) Digital mRNA proﬁling. Nat.
Biotechnol., 26, 293–294.
65. Gaudet, P., Argoud-Puy, G., Cusin, I., Duek, P., Evalet, O., Gat-
eau, A., Gleizes, A., Pereira, M., Zahn-Zabal, M., Zwahlen, C.
et al. (2013) neXtProt: organizing protein knowledge in the con-
text of human proteome projects. J. Proteome Res., 12, 293–298.
66. Cline, M.S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N.,
Workman, C., Christmas, R., Avila-Campilo, I., Creech, M.,
Gross, B. et al. (2007) Integration of biological networks and
gene expression data using Cytoscape. Nat.Protocols, 2, 2366–
2382.
5284 | Human Molecular Genetics, 2015, Vol. 24, No. 18
